View Single Post
Old 02-28-2022, 05:27 PM   #1134
Fuzz
Franchise Player
 
Fuzz's Avatar
 
Join Date: Mar 2015
Exp:
Default

Quote:
Novavax Inc NVAX.O said on Monday that an extended analysis of a late-stage study conducted in the United Kingdom showed that its COVID-19 vaccine provided long-term protection against the coronavirus.

The protein-based vaccine, NVX-CoV2373, continued to provide protection and maintained overall efficacy of 82.7% over a six-month period, the company said.

Additionally, vaccine efficacy of 82.5% was maintained against both symptomatic and asymptomatic infection, while vaccine efficacy against severe disease was 100%.

The analysis was conducted between November 2020 and May 2021 before the Delta and Omicron variants became dominant.
https://www.ctvnews.ca/health/corona...rial-1.5799676
Fuzz is offline   Reply With Quote